Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2017
18th World Conference on Lung Cancer
Access to all presentations that occur during the 18th World Conference on Lung Cancer in Yokohama, Japan
Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Download PDF of the Conference Program: Click Here.
Presentations will be available 24 hours after their live presentation time
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Presentations: 25
- Moderators:C. Bai
- Coordinates: 10/15/2017, 07:30 - 11:30, F203 (Annex Hall)
-
+
JCSE 01.10 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
10:05 - 10:20 | Presenter: Songtao Xu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
JCSE 01.11 - A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
10:20 - 10:35 | Presenter: Ying Cheng
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P1.01 - Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 80
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-003 - Patients Harboring a Novel PIK3CA Point Mutation after Acquired Resistance to Crizotinib in ROS1 Rearrangement Adenocarcinoma: A Case Report
09:30 - 09:30 | Author(s): M. Fang
- Abstract
Loading... -
+
P1.01-048 - Clinical Impact of EGFR Mutation on Brain Metastasis in NSCLC Patients: A Meta-Regression Analysis
09:30 - 09:30 | Presenter: Chien-Chung Lin
- Abstract
Loading...
-
+
P1.02 - Biology/Pathology
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 73
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.02-043 - A Comparison of Consistency of Detecting BRAF Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): M. Fang
- Abstract
Loading... -
+
P1.02-047 - Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations
09:30 - 09:30 | Author(s): Y. Zhu
- Abstract
Loading...
-
+
P1.03 - Chemotherapy/Targeted Therapy
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 53
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-045 - HER-2 Mutation Is Not a Prognostic Factor Treated with First-Line Chemotherapy in NSCLC Patients
09:30 - 09:30 | Author(s): C. Zhao
- Abstract
Loading... -
+
P1.03-046 - A Retrospective Analysis of Correlation Between Cytokines in TME and Therapeutic Effect of Advanced Lung Cancer Chemotherapy in China
09:30 - 09:30 | Author(s): J. Shen
- Abstract
Loading... -
+
P1.03-052 - Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
09:30 - 09:30 | Presenter: Yayi He
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 13
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
09:30 - 09:30 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P1.15 - SCLC/Neuroendocrine Tumors
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 17
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.15-016 - The Study of Population Pharmacokinetics and Individualized Dosage of Lobaplatin-Based Regimens in Elderly Patients with Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Ying Cheng
- Abstract
Loading...
-
+
P2.01 - Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 83
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-011 - The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma
09:00 - 09:00 | Presenter: Qingming Shi
- Abstract
Loading...
-
+
P2.02 - Biology/Pathology
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 75
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-003 - A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma
09:30 - 09:30 | Presenter: Xiaoshun Shi
- Abstract
Loading...
-
+
P2.03 - Chemotherapy/Targeted Therapy
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 59
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-047 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
09:30 - 09:30 | Presenter: Songtao Xu
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 14
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.04-003 - Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib
09:30 - 09:30 | Presenter: Li Zhang
- Abstract
Loading...
